INCUBETA
13.1.2021 13:14:36 CET | Business Wire | Press release
Lars Lehne has been appointed Group CEO of Incubeta , the independent digital marketing services group. The former SYZYGY AG CEO will be taking over from the founder Alan Lipschitz, whose company Interface made the reverse acquisition of IncuBeta Holdings in 2011. Alan will be moving into the role of Chairperson of the Board of Directors of Incubeta.
Lars brings with him more than 30 years of industry experience. Prior to Incubeta Lars spent four years as Global CEO at SYZYGY, a publicly listed WPP company. Before that, he spent seven years at Google as Country Director Agency DACH, paving the way for the tech giant quadrupling revenues in Germany. He has also held various senior management positions in agencies including Maxus, GroupM, Carat and MEC.
In addition to his current role as new Group CEO of Incubeta, Lars is a member of the advisory board of Yext, and betterplace.org, a Berlin based NGO. He’s also an Angel Investor in CLAIMINI GmbH. As Group CEO, Lars will be leading company positioning and growth, including its operations in North America, driving the business strategy and further uniting the group across the globe.
Incubeta operates across 14 countries with offices in cities including London, New York, Los Angeles, Madrid, Sydney and Cape Town. In 2013 the highly successful Net Media Planet (NMPi) was acquired, which established significant growth for Incubeta as it boosted its advertising offerings. The subsequent acquisition in 2016 of forward-thinking marketing technology specialist DQ&A, extended the company’s geographical and product growth. This was followed by the acquisition of market leading creative specialist, Joystick, in 2018. Through these acquisitions, Incubeta offers clients a full suite of unrivalled services connecting Media, Technology and Creative.
In the last twelve months, Incubeta has launched several new innovative platforms. This has included the award-winning proprietary Seamless technology, including Seamless Search – which measures the incrementality of paid and organic SEO keywords – and Seamless Creative – which unifies media activity and creative assembly at scale. The company has also made a series of new appointments including senior hire John Cawdery as US CEO.
Alan Lipschitz, Founder and Chairperson of the Board, comments: “Having started a small South African business many years ago, I am so very proud of how far the company has come. By building a fantastic team around me and adding inspirational businesses from around the world, Incubeta has grown into a leading player in digital marketing services. The company is in a great place, yet I believe in order to accelerate pace and to meet the challenges of the future we need a different type of leader.
“I have the utmost faith Lars is the leader the company needs to take Incubeta forward. He has the expertise to bring the team further together, drive clear strategy, and build on the fantastic foundation I have been able to create with my wonderful team. So it is with great pride and pleasure that I hand the mantle of Chief Executive Officer of the Incubeta Group to Lars Lehne.”
Lars Lehne, Group CEO of Incubeta, comments: “I’m thrilled and honoured to be joining such a forward-thinking and innovative company. Incubeta has continued to grow during one of the most challenging years for the industry which is a testament to the quality and hard work of every team member across the globe. The company has flourished under Alan’s leadership and it's a great privilege that he’s trusting me to take his dream forward.
“As marketing continues to evolve at a rapid pace, it’s harder now than ever before for brands to connect with their customers. By integrating Media, Technology, and Creative in a seamless way Incubeta has developed the right services and products to help clients grow in a digital world. Incubeta puts the ownership of the customer experience back into the hands of its clients. I can’t wait to see what the next chapter for Incubeta looks like.”
-ENDS-
About Incubeta:
Incubeta is the union of three market leading specialists in Technology, Media, and Creative – DQ&A, NMPi, and Joystick respectively. By seamlessly integrating these three specialisms and rethinking the rules of marketing, Incubeta puts the ownership and control of the customer experience back in the hands of the advertiser, both brands and agencies.
As the largest and longest established GMP sales partner in EMEA and APAC, Incubeta has proven through working with top-tier brands that they are leading specialists in helping advertisers tackle complex projects such as in-housing, dynamic creative, data integration, real 1:1 marketing, and industry-specific segmentation modeling. Incubeta is primed to help advertisers deliver complex use cases across Google's Maturity Framework and Menu of Services.
Find out more at: incubeta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005451/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
